CROI 2015 Program and Abstracts

Poster Listings

Session P-N9 Poster Session

Poster Hall

701 Revaccinating HIV+ Adults With Double vs Standard HBV Regimen: ANRS B-BOOST Trial David Rey 1 ; Cécilie Dufour 2 ; Marie-JoséeWendling 3 ; Patrick Miailhes 4 ; Philippe Sogni 8 ; Georges Haour 2 ; Marie-Louise Michel 7 ; Lionel Piroth 6 ; Odile Launay 5 ; Fabrice Carrat 2 1 University Hospital Strasbourg, Strasbourg, France; 2 Université Pierre et Marie Curie, Strasbourg, France; 3 Hôpitaux Universitaires Strasbourg, Strasbourg, France; 4 University Hospital of Lyon, Lyon, France; 5 CIC Vaccinologie, Paris, France; 6 University Hospital of Dijon, Dijon, France; 7 Institut Pasteur, Paris, France; 8 Cochin Hospital, Paris, France 702 Complex HBV Quasispecies Affects Immunogenicity in Acute Hepatitis B Infection Valentina Svicher 1 ; Marianna Aragri 1 ; Nicola Coppola 2 ; Claudia Alteri 1 ; Arianna Battisti 1 ; Caterina Sagnelli 2 ; Mariantonietta Pisaturo 2 ; MariaConcetta Bellocchi 1 ; Evangelista Sagnelli 2 ; Carlo-Federico Perno 1 1 University of Rome Tor Vergata, Rome, Italy; 2 Second University of Naples, Naples, Italy Anchalee Avihingsanon 1 ; Opass Putcharoen 2 ; Salyavit Chittmittrapap 2 ;Tanakorn Apornpong 1 ;Vorapot Sapsirisavat 1 ; Sasiwimol Ubolyam 1 ; Stephen J. Kerr 1 ; Kiat Ruxrungtham 1 On behalf of the HIV-NAT 105 StudyTeam 1 HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross - AIDS Research Centre, Patumwan, Thailand; 2 Chulalongkorn University, Bangkok, Thailand 704 Occult HBV/HIV Coinfection and Validation of Cost-Effective NAT Pooling PCR Shanmugam Saravanan 1 ; Janardhanan Mohanakrishnan 1 ;Thongadi Ramesh Dinesha 1 ; Jayaseelan Boobalan 1 ; Pachamuthu Balakrishnan 1 ; Kailapuri G Murugavel 1 ; Sunil S Solomon 2 ; Suniti Solomon 1 ; Davey M. Smith 3 1 YRG Centre for AIDS Research and Education, Chennai, India; 2 Johns Hopkins University School of Medicine, Baltimore, MD, US; 3 University of California San Diego, San Diego, CA, US Matteo Basilissi 1 ; CamillaTincati 1 ; Esther Merlini 1 ; Elisabetta Sinigaglia 2 ; Javier Sanchez- Martinez 2 ; Giovanni Carpani 2 ; Antonella d’Arminio Monforte 1 ; Laura Milazzo 1 ; Giulia Marchetti 1 1 University of Milan, Milan, Italy; 2 San Paolo Hospital, Milan, Italy 706 Effect of Immunosuppression and Antivirals on Intracellular HBV Replication in HIV-HBV Coinfection Anders C. Boyd 1 ; Karine Lacombe 1 ; Fabien Lavocat 2 ; Sarah Maylin 3 ; Patrick Miailhes 4 ; Caroline Lascoux-Combe 5 ; Constance Delaugerre 3 ; Pierre-Marie Girard 1 ; Fabien Zoulim 2 1 Inserm UMR_S1136, Paris, France; 2 Inserm U1052, Lyon, France; 3 Inserm U941, Paris, France; 4 Hospices Civils de Lyon, Lyon, France; 5 Hôpital Saint-Louis AP-HP, Paris, France 707 Prevalence of HDV in a Midwestern HIV-HBV Coinfected Population Sanam Razeghi ; Susan Rouster; Kenneth E. Sherman University of Cincinnati, Cincinnati, OH, US 708LB Oral Prenylation InhibitionWith Lonafarnib in Chronic Hepatitis D Infection: A Randomized, Double-Blinded, Placebo-Controlled Proof-of- Concept Study Christopher Koh 1 ; Laetitia Canini 7 ; Harel Dahari 2 ; David Cory 3 ; Ingrid Choong 3 ; David Kleiner 4 ; Stewart Cooper 6 ; Mark A.Winters 5 ; Jeffrey Glenn 5 ;Theo Heller 1 1 National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Fulton, MD, US; 2 Loyola University Medical Center, Maywood, IL, US; 3 Eiger BioPharmaceuticals, San Carlos, CA, US; 4 National Cancer Institute, Bethesda, MD, US; 5 Stanford University, Stanford, CA, US; 6 California Pacific Medical Center, Palo Alto, CA, US; 7 University of Edinburgh, Edinburgh, United Kingdom 709 Incidence of Hepatitis E Virus in HIV-Infected Patients: A Longitudinal Prospective Study Antonio Rivero-Juarez 1 ; Loreto Martinez-Dueñas 1 ; Antonio Martinez-Peinado 2 ; Angela Camacho 1 ; Celia Cifuentes 3 ; Ana Gordon 1 ; Mario Frias 1 ; JulianTorre-Cisneros 1 ; Juan A. Pineda 3 ; Antonio Rivero 1 1 Instituto Maimonides de Investigación Biomédica de Córdoba, Cordoba, Spain; 2 Instituto Maimonides de Investigación Biomedica de Córdoba, Cordoba, Spain; 3 Hospital Universitario de Valme, Seville, Spain 703 Higher Rate of Hepatitis B Antigen and Anti-HBV Antibody Seroconversion Among HIV/Chronic Hepatitis B Coinfection Initiating HBV Active HAART From Thailand 705 Invariant Natural Killer T-Cells in HIV-HBV Coinfection

2:30 pm– 4:00 pm Mental Health and Treatment Adherence with Direct-Acting Antivirals 694 Impact of Baseline Mental Health on Adherence to Interferon-Free HCV Therapy Jack Masur 1 ; LydiaTang 1 ; Amy Nelson 1 ; Anu Osinusi 1 ; Anita Kohli 2 ; Rachel Silk 2 ; Chloe Gross 2 ; Sarah Kattakuzhy 2 ; Michael Polis 3 ; Shyam Kottilil 1 1 University of Maryland, Baltimore, MD, US; 2 National Institutes of Health, Bethesda, MD, US; 3 National Institutes of Health, Bethesda, MD, US 695 Mental Health Impact of HCV Treatment in HIV/HCV Patients: DAA vs IFN-Based Therapy Louise Lundgren 1 ; Sarah Kattakuzhy 2 ; Angie Price 2 ; Catherine Seamon 3 ; Amy Nelson 4 ; Anita Kohli 2 ; Rachel Silk 2 ; Chloe Gross 2 ; Henry Masur 1 ; Shyamasundaran Kottilil 4 1 National Institutes of Health Clinical Center, Bethesda, MD, US; 2 Leidos Biomedical Research, Inc, Frederick, MD, US; 3 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, US; 4 Institute of Human Virology, University of Maryland, Baltimore, MD, US 2:30 pm– 4:00 pm HCV: Resistance to Antiviral Agents 696 Characterization of Naturally Occurring Resistance to HCV NS5A Inhibitors Jennifer Cook; Owen Solberg; Alicia Newton; Suqin Cai; Arne Frantzell; Jacqueline Reeves; Christos J Petropoulos; JonathanToma; Wei Huang Monogram Biosciences, South San Francisco, CA, US 697 Hepatitis C Q80K Prevalence in BC, Canada, Determined by a Public Domain Assay Jeffrey B. Joy 1 ; Celia K. Chui 1 ; Chanson J. Brumme 1 ; Mel Krajden 2 ; Andrea Olmstead 2 ; Winnie Dong 1 ;Wendy Zhang 1 ; Aram Karakas 1 ; Huong Hew 3 ; Richard Harrigan 1 1 BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 2 BC Centre for Disease Control, Vancouver, Canada; 3 Janssen Pharmaceuticals, Inc., Toronto, Canada 698 HCVNS3 Variants in HIV/HCV Coinfected Patients Before-After PegIFN/ Ribavirin Enass Abdel-Hameed 1 ; Susan D. Rouster 1 ; Xiang Zhang 2 ; Jing Chen 2 ; Mario Medvedovic 2 ; Kenneth E. Sherman 1 1 University of Cincinnati, Cincinnati, OH, US; 2 University of Cincinnati, Cincinnati, OH, US 699 Compensatory Mutations in HCV NS5A/B Coevolve in Patients Failing NS3 Inhibitors Velia Chiara Di Maio 1 ;Valeria Cento 1 ; Daniele Di Paolo 2 ; Sergio Babudieri 3 ; GloriaTaliani 4 ; Giustino Parruti 5 ; Giuliano Rizzardini 6 ; Mario Angelico 2 ; Carlo Federico Perno 1 ; Francesca Ceccherini-Silberstein 1 1 University of Rome Tor Vergata, Rome, Italy; 2 University Hospital of Rome Tor Vergata, Rome, Italy; 3 University of Sassari, Sassari, Italy; 4 University of Rome La Sapienza, Rome, Italy; 5 Pescara General Hospital, Pescara, Italy; 6 Hospital Sacco of Milan, Milan, Italy 2:30 pm– 4:00 pm Other Hepatitis Viruses: HBV, HDV, HEV 700 Hepatitis B Vaccine Response in Children Attending Rwanda Military Hospital Judy T. Orikiiriza 1 ; Louis Mujuwisha 2 ; Elizabeth Karlsson 3 ;Vincent Mutabazi 4 ; Johan Normark 3 1 Infectious Diseases Institute Makerere College of Health Sciences, Kampala, Uganda; 2 University of Rwanda, Kigali, Rwanda; 3 Umea Infectious Diseases Institute, Kigali, Sweden; 4 Rwanda Biomedical Center, Kigali, Rwanda Session P-N10 Poster Session Poster Hall Session P-N11 Poster Session Poster Hall

Poster Listings

55

CROI 2015